Company Focus
Novartis
Latest Novartis News
Biotechnology
Swiss pharma giant Novartis on Friday revealed it has broken ground on a new, state-of-the-art global Biomedical Research center in San Diego, California, USA, designed to provide world-class scientific infrastructure and drug-discovery capabilities to advance the company’s pipeline for patients. 7 February 2026
Related News
Insights
Company Spotlight
A clinical-stage biopharma company developing selective fatty acid synthase (FASN) inhibitors for diseases driven by dysregulated lipid metabolism and fibrosis, with current priorities in MASH and acne.
Latest News & Features of interest to Novartis
Pharmaceutical
Health Canada has authorized Livmarli (maralixibat) oral solution and tablet formulation for the treatment of cholestatic pruritus in patients aged 12 months or older with progressive familial intrahepatic cholestasis (PFIC), Mirum Pharmaceuticals announced on Friday. 7 February 2026
Biotechnology
Swiss pharma giant Novartis on Friday revealed it has broken ground on a new, state-of-the-art global Biomedical Research center in San Diego, California, USA, designed to provide world-class scientific infrastructure and drug-discovery capabilities to advance the company’s pipeline for patients. 7 February 2026
article
US biotech Eikon Therapeutics has raised about $381 million in the largest biotech IPO of the year so far, but the market’s first reaction was cautious. Shares fell nearly 17% on their first day of trading, closing at $15. 6 February 2026
Biotechnology
Chinese biotech Kelun-Biotech has won a new approval from China’s National Medical Products Administration for sac-TMT (sacituzumab tirumotecan), a TROP2-directed antibody-drug conjugate. 6 February 2026
Biotechnology
Privately-held San Diego biotech ADARx Pharmaceuticals announced the appointment of Dr Donald Fong as chief medical officer (CMO) to lead the advancement of its clinical-stage pipeline. 6 February 2026
Pharmaceutical
German drugmaker Bayer has revealed positive late-stage results for its investigational once-daily oral anticoagulant asundexian. 6 February 2026
Biotechnology
California-based Braveheart Bio, a biotech developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, has announced that Marc Evanchik has been promoted to chief scientific officer (CSO). 5 February 2026
Pharmaceutical
US pharma major Bristol Myers Squibb reported fourth-quarter 2025 revenues of $12.5 billion, up 1%, with GAAP earnings per share of $0.53 and non-GAAP EPS of $1.26. Full-year revenues were $48.2 billion, essentially flat, while non-GAAP EPS rose to $6.15. 5 February 2026
Biotechnology
A study funded by Israeli pharma and generics player Teva has contributed to the growing body of real-world evidence (RWE) supporting Ajovy (fremanezumab) as an effective migraine-preventive therapy in patients with chronic migraine (CM) and episodic migraine (EM). 5 February 2026
Biotechnology
California, USA-based Coherus Oncology has entered into a clinical supply agreement with JUS healthcare giant Johnson & Johnson to evaluate tagmokitug (CHS-114). 5 February 2026
Latest In Brief for Novartis
Pharmaceutical
French nephrology specialist Advicenne has announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Sibnayal (ADV7103), a fixed combination of potassium citrate and potassium bicarbonate for the treatment of distal renal tubular acidosis (dRTA). 19 January 2026
Latest Ones To Watch News
US pharma major Merck has ended discussions to acquire Revolution Medicines after the two sides failed to align on price, cooling a process that had briefly dangled a valuation of around $30 billion for the RAS-focused biotech. 2 February 2026
20 January 2026
16 January 2026
15 January 2026
13 January 2026
Ones to Watch Companies
Refine search
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze